Cabaletta Bio Inc. (CABA)
1.27
0.00 (0.00%)
At close: Apr 25, 2025, 3:59 PM
1.30
2.36%
Pre-market: Apr 28, 2025, 06:11 AM EDT
0.00% (1D)
| Bid | 1.25 |
| Market Cap | 62.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -115.86M |
| EPS (ttm) | -2.34 |
| PE Ratio (ttm) | -0.54 |
| Forward PE | -0.48 |
| Analyst | Buy |
| Ask | 1.35 |
| Volume | 320,265 |
| Avg. Volume (20D) | 1,057,175 |
| Open | 1.26 |
| Previous Close | 1.27 |
| Day's Range | 1.23 - 1.31 |
| 52-Week Range | 0.99 - 13.50 |
| Beta | 2.44 |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART,...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 161
Stock Exchange NASDAQ
Ticker Symbol CABA
Website https://www.cabalettabio.com
Analyst Forecast
According to 8 analyst ratings, the average rating for CABA stock is "Buy." The 12-month stock price forecast is $22.5, which is an increase of 1671.65% from the latest price.
Stock Forecasts5 months ago
-19.84%
Cabaletta Bio shares are trading lower after Wells...
Unlock content with
Pro Subscription
8 months ago
-34.37%
Cabaletta Bio shares are trading lower. The company reported Q2 financial results.
